Overview
Michael Reinhardt practices practicing medicine in Oldenburg, Germany.
His clinical expertise encompasses Endometrial Cancer, Vaginal Cancer, and Cervical Dysplasia.
He is actively involved in clinical research, co-authoring 10 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Michael J. Reinhardt
Is Michael J. Reinhardt a top-rated expert for Endometrial Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Michael J. Reinhardt is classified as an Experienced expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Michael J. Reinhardt participate in research or clinical trials?
Yes. Michael J. Reinhardt has published 10 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Michael J. Reinhardt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Cervical DysplasiaMr. Reinhardt isExperienced. Learn about Cervical Dysplasia.
- Endometrial CancerMr. Reinhardt isExperienced. Learn about Endometrial Cancer.
- Vaginal CancerMr. Reinhardt isExperienced. Learn about Vaginal Cancer.